Vonsetamig

N/A

Report date: 2026/04/14 20:00:15

Base Information

Drug NameVonsetamig

Drug Alias NameREGN-5459

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibodyBiologics > T cell engagers

Mechanisms of ActionAnti-CD3Anti-BCMA

TargetsT cell surface glycoprotein CD3B-cell maturation protein

Therapy Area/IndicationsRenal Insufficiency, ChronicLupus NephritisMultiple Myeloma

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited StatesTaiwanGermany +[5]

CombinationsNo

Global Highest StatusPhase 2 Clinical

Highest Status in ChinaN/A

Originator CompaniesRegeneron Pharmaceuticals Inc

China Registration ClassN/A

Develop Information

Active CompaniesRegeneron Pharmaceuticals Inc

Inactive CompaniesN/A

Active IndicationsRenal Insufficiency, ChronicLupus NephritisMultiple Myeloma

Inactive IndicationsN/A

Other Information

ATC CodeN/A